TE Tirzepatide Editorial

Tool

Tirzepatide Dose-Surcharge Comparison

Released: · Last reviewed:

Direct answer

Tirzepatide dosing escalates, so the price you enrol at is often not the price you pay at a maintenance dose. This tool models what a dose-related surcharge does to your total cost, which can reverse which provider is cheaper within months. Dose-coverage terms are unverified across our provider dataset.

Key takeaways

  • The dose you enrol at is rarely the dose you stay on, so enrolment pricing can mislead.
  • A surcharge applied above a dose threshold can reverse which provider is cheapest.
  • Dose-coverage terms are unverified for every provider in our dataset.
  • Ask specifically what the price becomes at 10 mg and 15 mg before committing.
  • This tool runs in your browser; nothing you enter is transmitted or stored.
Key facts
What it modelsCost impact of a dose-related surcharge over time
Why it mattersEscalation means the enrolment dose is temporary
Dataset statusDose-coverage terms unverified for all providers
Question to askWhat is the price at 10 mg and at 15 mg?
Data handlingRuns entirely in your browser
Verified
Medical reviewers Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Released 2026-07-22
Updated
Price verified 2026-09-04
Methodology v4.1
Note. This calculator runs entirely in your browser. No values you enter are transmitted or stored.

Model a dose surcharge

Why is dose coverage the question people forget?

Because at enrolment you are on a starting dose and the question feels hypothetical. By month four or six it is not hypothetical at all, and by then you may have prepaid a commitment. A surcharge of $50 monthly applied for twenty of twenty-four months is $1,000 — frequently more than the difference that led someone to choose one provider over another.

What should you ask before enrolling?

What the total monthly cost becomes at 10 mg and at 15 mg, in writing. Not whether higher doses are 'available' — what they cost. A provider that cannot answer that clearly before payment has told you something about how the pricing works.

Related: Higher-dose providers · True-cost calculator

What do the verified rates look like?

Mondae$114NexLife$115TRYM Health$125Eden$129Sprout Health$149He & She MD$159Bodybuilding Health+$174.67TelePep$214Yucca Health$225Join Josie$233.25Found$239Pallas Health$239Fridays$240Enhance.MD$280Zappy Health$299
The lowest monthly figure each program prints on a standing plan, November 8, 2026. A low monthly figure usually requires prepaying 6 or 12 months; compare the twelve-month cost in the index before choosing.
Data for: Lowest standing monthly figure per program
ProgramAmount
Mondae$114
NexLife$115
TRYM Health$125
Eden$129
Sprout Health$149
He & She MD$159
Bodybuilding Health+$174.67
TelePep$214
Yucca Health$225
Join Josie$233.25
Found$239
Pallas Health$239
Fridays$240
Enhance.MD$280
Zappy Health$299

What does this page cover, and what does it deliberately leave out?

This page addresses Dose tiers, included maximum and surcharge and recurring cost, organised around the primary question of tirzepatide dose surcharge. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.

Scope of this page and the basis for each element
ElementTreatment hereEvidence basis
Dose tiersCovered on this pageRegulatory or policy source
Included maximumCovered on this pageRegulatory or policy source
Surcharge and recurring costCovered on this pageRegulatory or policy source
Individualized clinical instructionDeliberately not coveredBelongs with the provider's own quotation

What are the limits of what this page can tell you?

Every page on this site rests on a specific figures you enter, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.

Specific limitations.
  • The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the provider's own quotation.
  • Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
  • Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
  • Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.

What would change the conclusion on this page?

Any of the following would change what this page concludes:

  • New primary evidence bearing directly on tirzepatide dose surcharge.
  • A change to FDA labelling affecting any statement made above.
  • A verified correction submitted through the corrections process and accepted on the evidence.
  • A material change to a captured record, including a price, term, or regulatory status.
  • Completion of a verification currently marked pending, which would replace a gap with a stated fact.

Frequently asked questions

Do all providers charge more for higher doses?

Some hold price flat and some apply surcharges. This term is unverified for every provider in our dataset.

How much can a surcharge change my total?

Substantially — a $50 monthly surcharge over twenty months is $1,000, often more than the difference between providers at enrolment.

What should I ask before signing up?

What the total monthly cost is at 10 mg and 15 mg, in writing.

Is my input stored?

No. The tool runs in your browser only.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Change history

Substantive changes to this page
DateChange
2026-07-22Page published with current dataset snapshot.
2026-09-04Shared cost components and disclosures rebuilt from the 2026-09-04 dataset (NexLife September 2026 card re-read live; Yucca Health and a program since removed from this site added; NexLife disclosed as a commercial partner, labelled where it appears).
2026-11-08Updated for November 2026: prices, methodology labels (v4.1) and disclosures brought to the November 8, 2026 dataset; researcher and both medical reviewers named.

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?